Author Archives: "Coach" Israel Barken M.D.

Cryo Immunotherapy Part 2

Posted on June 26, 2015

Part 2 of the lecture about Cryo Immune Therapy given by Dr. Israel  Barken from the Prostate Research and Education Foundation.  Dr. Barken describes Cryo immunotherapy. The reasons why there are no consistent immune response after cryoablation are discussed.  Suggestions … Continue reading →

Posted in Cryo Immunotherapy, Cryoablation, Prostate Cancer, Treatments for Prostate Cancer | Leave a comment

Cryo Immunotherapy Part 1

Posted on June 19, 2015

Dr. Barken presents the history of cryoablation and the new developments in the field of immunology which will create enhancement of the Immune effect on metastatic disease in response to cryoablation of local tumor.

Posted in Cryo Immunotherapy, Cryoablation, Immune Therapy, Metastatic Disease, Metastatic Prostate Cancer Disease, Treatments for Prostate Cancer, Vaccine | Leave a comment

Cryoablation Immuno Therapy

Posted on June 9, 2015

Clinical Study Phase I Cryoimmunotherapy against Metastatic prostate Cancer Disease. Dr. Israel Barken, the Medical Director of the Prostate Cancer Research and Education, presents a clinical study phase I, featuring cryosurgery plus immuno-Modulator – Cyclophosphamide and Anti CTLA 4 Antibodies- … Continue reading →

Posted in Castration Resistant Prostate Cancer, Clinical Trials, Immune Therapy, Prostate Cancer, Treatments for Prostate Cancer, Vaccine | Leave a comment

Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer

Posted on May 3, 2015

Phase I study approach of priming the immune system with Prostvac vaccination, intensified immunotherapy with Ipilimumab to further enhance the immune response.  This was presented by Hapreet Singh M.D. from the National Cancer Institute. Genentech video explaining the “Security Checkpoint System” … Continue reading →

Posted in Ask Dr. Barken, Immune Therapy, Metastatic Prostate Cancer Disease, Treatments for Prostate Cancer, Vaccine | Leave a comment

Percentage Involved Core Length and Risk of Recurrence After Radical Prostatectomy

Posted on April 24, 2015

Article: Greatest Percentage Involved Core Length and Risk of Clinically Significant Prostate-Specific Antigen Failure After Radical Prostatectomy. Author:  Anthony V. D’Amico Source: Clinical Genitourinary Cancer.  March 5, 2015

Posted in Biopsy, Prognosis, Prostate Cancer, PSA, Survival prostate cancer, Treatments for Prostate Cancer | Leave a comment

Active Surveillance In Intermediate-Risk Prostate Cancer

Posted on April 6, 2015

Active Surveillance In Intermediate-Risk Prostate Cancer Called Into Question. https://youtu.be/dBk3z2T9KwQ Dr. Israel Barken brings info about higher risk of cancer specific mortality in the intermediate prostate cancer risk group. The study presentor at the GenitoUrinary Symposium 2015 was Dr. Andrew … Continue reading →

Posted in Active Surveillance, Treatments for Prostate Cancer | Tagged , | 1 Comment

Testosterone and the risk of cancer.

Posted on March 27, 2015

Testosterone and the risk of cancer. Dr. Israel Barken , the medical director of the prostate cancer research and education foundation PCREF discusses a recent article in the BJU Int. 2015 Feb;115(2):317-21.. Testosterone therapy and cancer risk. Eisenberg ML1, Li … Continue reading →

Posted in Testosterone | Tagged , , | Leave a comment

Circulating Epithelial Tumor Cells and Tumor Spheres

Posted on March 13, 2015

Circulating Epithelial Tumor Cells (CETC) and Tumor Spheres. Discussion with Prof. Katharina Pachmann, Ph.D, M.D who is the medical Doctor in Jena University Hopital’s Department of Experimental Hematology and Oncology.  She is an expert on Circulating Epithelial Tumor Cells. The … Continue reading →

Posted in Cancer Stem Cells, CETC, CTC, Prognosis, Prostate Cancer, Treatments for Prostate Cancer, Tumor Spheres | Leave a comment

Prostvac Vaccination for Localized Prostate Cancer Disease

Posted on March 6, 2015

Prostvac in Preventing Disease Progression in Patients with Localized Cancer Undergoing Active Surveillance. What is unique about  this vaccine study , is the fact that it is given to patients with localized disease.  Practically, the patient gets a series of vaccination … Continue reading →

Posted in Active Surveillance, Clinical Trials, Immune Therapy, Treatments for Prostate Cancer, Vaccine | Tagged , | Leave a comment

What is Liquid Biopsy- The Role of Exosomes

Posted on March 2, 2015

Liquid Biopsy – The Role of Exosomes. Dr. Israel Barken introduces the videos published by Life Technologies from ThermoFisher Technologies. The introduction relates to the importance of using imaging and markers to define recurrent disease and monitor the progression. The … Continue reading →

Posted in Biomarker, CETC, CTC, Exosome, Genome, Imaging, Liquid Biopsy, Markers, Treatments for Prostate Cancer | Tagged | Leave a comment